Skip to main content

Table 2 Multivariate CRC-specific survival analysis of different clinical stages in CRC patients with different sites

From: Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer

  Cecum Ascending colon HR (95% CI) Transverse colon HR (95% CI) Descending colon HR (95% CI) Sigmoid colon HR (95% CI) Rectum HR (95% CI)
Stage at presentation
 Stage 0 1.00 0.64 (0.48–0.85)* 1.18 (0.8–1.74) 1.25 (0.91–1.74) 0.98 (0.69–1.4) 1.14 (0.71–1.84)
 Stage I 1.00 0.58 (0.54–0.61)** 0.86 (0.79–0.93)** 1.07 (1–1.15)* 1.03 (0.95–1.1) 1.05 (0.96–1.16)
 Stage II 1.00 0.57 (0.54–0.6)** 0.78 (0.73–0.84)** 1 (0.95–1.06) 0.94 (0.89–0.99)* 0.91 (0.85–0.98)*
 Stage III 1.00 0.55 (0.52–0.58)** 0.81 (0.75–0.87)** 1.1 (1.03–1.18)* 0.98 (0.91–1.05) 0.87 (0.8–0.95)*
 Stage IV 1.00 0.58 (0.5–0.66)** 0.88 (0.75–1.04) 1.11 (0.96–1.28) 1.07 (0.92–1.24) 0.94 (0.78–1.13)
 All stages 1.00 0.56 (0.54–0.57)** 0.82 (0.78–0.85)** 1.07 (1.04–1.11)** 0.98 (0.95–1.02) 0.94 (0.89–0.98)*
  1. ** p < 0.001, *p < 0.05; CI confidence interval, HR hazard ratio. The classification criteria of stages refer to the AJCC/UICC TNM staging system. The cecum cancer group was set to 1 as the control group